Overall, these data suggest that serum miR-301a, in combination with examination of TGF-β and IL-6, might be a fibrosis marker for fibrosis in patients with chronic pancreatitis and early pancreatic cancer. The gene discussed is IL6; the disease is chronic pancreatitis.